Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
Release time：2021-07-16 13:16
Suzhou, July 16, 2021 - 真人直营投注网站 (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay’s Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
The first hospital to use proxalutamide under the EUA, Hospital Barrio Obrero, part of Paraguay’s MSPBS network, has reported promising initial results. Of the first 25 COVID-19 inpatients treated with Proxaluatmide, only 1 patient (4%) died. Such mortality rate was lower than the usual mortality rate of COVID-19 patients in Paraguay. In addition, proxalutamide has demonstratd potential benefits in 7 of the patients who initially required high flow oxygen.
Dr. Youzhi Tong, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "We are delighted to see that proxalutamide is saving lives in Paraguay following the EUA from the MSPBS. We are actively exploring additional EUAs of proxalutamide in other countries and regions to help COVID-19 patients around the world."
recommend News
2024-07-01
2024-06-05
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn